RevBio
RevBio is a clinical-stage medical device company developing TETRANITE, a patented synthetic injectable bone adhesive bioengineered from sandcastle worm protein, currently in first-in-human trials for dental, neurosurgical, orthopaedic, and veterinary applications.
- Company typePrivate
- Founded2014
- HeadquartersLowell, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What RevBio does
RevBio (formerly LaunchPad Medical) is a clinical-stage medical device company founded in 2014 by Brian Hess and headquartered in Lowell, Massachusetts at the University of Massachusetts M2D2 incubator. The company is developing TETRANITE, a synthetic, injectable, self-setting, load-bearing bone adhesive biomaterial bioengineered from a protein secreted by the sandcastle worm. The platform combines Tetracalcium Phosphate with O-Phospho-L-Serine in an aqueous medium that sets within minutes to a multiphasic solid exhibiting shear bond strength up to 3 MPa (similar to human cancellous bone) and compression strength of 30 MPa. TETRANITE is osteoconductive and biodegrades over time, transferring load-bearing responsibility to newly regenerated bone. RevBio holds 10+ patents on the technology with active prosecution worldwide, and the founder personally holds 18 patents in the field.
The company is concurrently advancing first-in-human clinical trials across multiple indications: dental implant stabilization, dental ridge augmentation, dental bone grafting, cranial flap fixation, distal radius (wrist) fracture fixation, vertebral compression fractures, and canine veterinary dental procedures. FDA approvals have been granted for pilot trials in extremity fractures (November 2025), dental ridge augmentation (December 2025), and a pivotal trial for cranial flap fixation (January 2026). The company received ISO 13485:2016 certification in May 2023 and secured CMS reimbursement for cranial flap fixation in December 2024. Active clinical sites operate in the United States, United Kingdom, and Italy, and research collaborations are with University of Pittsburgh, Dartmouth College, Duke University, and the Michigan-Pittsburgh-Wyss Regenerative Medicine Center.
RevBio's revenue model will be anchored in direct sales of TETRANITE to hospitals, dental practices, and veterinary clinics once FDA approvals are obtained, supplemented by technology licensing arrangements (a definitive license agreement with Stryker Corporation was executed in 2015). To date, the company is pre-revenue and has been funded through a combination of non-dilutive NIH SBIR/STTR grants (exceeding $9 million cumulatively from NIH, NASA, the U.S. Department of Defense, and private foundations), a strategic investment from Pacific Dental Services (February 2023), and an angel/strategic round of approximately $9 million raised in mid-2021. The executive team includes CEO/Founder Brian Hess (former Stryker engineer, co-inventor), COO/CFO D. Grayson Allen, CSO George Kay (Harvard faculty), and CMO Kevin Foley (University of Tennessee). RevBio is targeting a $10 billion+ total addressable market spanning neurosurgical, orthopaedic, and dental applications.
RevBio firmographics
Firmographics- Name
- RevBio
- Legal name
- RevBio Inc.
- Website
- https://revbio.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- RevBio is a clinical-stage medical device company developing TETRANITE, a patented synthetic injectable bone adhesive bioengineered from sandcastle worm protein, currently in first-in-human trials for dental, neurosurgical, orthopaedic, and veterinary applications.
- Ownership category
- akta.pro rank
RevBio industry classification
Industry- Product category
- Orthopedic Biomaterials
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)
- akta.pro secondary industries
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)
Keywords
Where RevBio is headquartered
LocationHeadquarters
- HQ city
- Lowell
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RevBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- TETRANITE Bone Adhesive Sales: Pre-revenue clinical stage company. Revenue will be generated from sales of TETRANITE regenerative bone adhesive for dental, cranial, orthopaedic, and veterinary applications once FDA approvals are obtained.
- Technology Licensing: Company holds licensing agreements for its technology and is actively pursuing patent protection for additional compositions and methods of use.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
RevBio product offering
Product offeringCore offering
RevBio develops and is commercializing TETRANITE, a patented, synthetic, injectable, self-setting, load-bearing, osteoconductive bone adhesive biomaterial. The product is engineered to bond bone-to-bone and bone-to-metal in wet surgical environments, replacing the need for metal fixation hardware in dental, cranial, orthopaedic, and veterinary procedures. RevBio is a clinical-stage medical device company running first-in-human clinical trials across multiple indications ahead of commercial launch.
Product overview
RevBio offers TETRANITE®, a single patented regenerative bone glue platform technology. The product is a synthetic biomaterial that functions as both a fixation and fusion device, with applications across multiple medical segments including dental (implant stabilization, bone grafting, ridge augmentation), neurosurgical (cranial flap fixation), orthopaedic (fracture fixation, extremity repair, spinal treatment), and animal health (veterinary dental procedures). The company is conducting multiple clinical trials across these indications, with the core TETRANITE technology serving as the foundation for all product applications.
Differentiator
Problem solved
Functional benefit
Products and services
- TETRANITE®
Quantifiable outcome
- Withstands tensile and shear bond stresses up to 3 MPa, similar to cancellous bone strength
- +5 more outcomes
Companies that use RevBio
Customer profileNamed customers1 record
Segments5 records
Ideal customer profiles4 records
RevBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
RevBio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Stryker CorporationcoreRevBio executed a definitive license agreement with Stryker for novel bone adhesive technology originally co-invented by Brian Hess during his tenure at Stryker. Brian previously developed and launched HydroSet, a commercially successful synthetic bone substitute, which is a key predicate to TETRANITE technology.
- Massachusetts Medical Device Development Center (M2D2)coreRevBio operates from M2D2 technology incubator located at University of Massachusetts Lowell campus, with access to laboratory suite for product development, quality control, and manufacturing.
- University Research CollaboratorscoreUniversity-based research partners including University of Pittsburgh (Guiseppe Intini), Dartmouth College (Doug Van Citters), Duke University (Ken Gall). Collaborators contribute to indication-specific product development and preclinical testing.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
RevBio competitors and assessment
Company assessmentBroad incumbents
- Medtronic: Medtronic is a leading medical device incumbent across spine, orthopaedics, and cranial/surgical procedures, with a broad orthobiologics portfolio including bone graft substitutes and recombinant bone morphogenetic proteins. Its established spine and neurosurgery channels will compete directly with TETRANITE in spine and cranial indications.
- Baxter International: Baxter markets Tisseel, a fibrin sealant widely used in surgical applications for tissue sealing and hemostasis, and Evicel. These products compete with TETRANITE's wet-field adhesion properties across surgical specialties and represent the incumbent benchmark for surgical sealants that RevBio must differentiate against.
- Becton Dickinson (BD): Becton Dickinson has a significant surgical and biosurgery portfolio including hemostatic agents, sealants, and tissue adhesives (e.g., Progel, Arista AH). It competes with TETRANITE's wet-field surgical adhesive positioning across multiple procedural specialties and represents an incumbent benchmark.
- Johnson & Johnson (DePuy Synthes): Johnson & Johnson's DePuy Synthes franchise is a global orthopaedics leader with trauma, spine, and surgical biomaterials portfolios. It competes with TETRANITE in fracture fixation and orthopaedic indications and has the surgeon relationships and hospital contracts RevBio will need to build post-approval.
- Stryker Corporation: Stryker is a global medical device leader in orthopaedics, dental, and surgical equipment. It is RevBio's most strategically relevant comparator because Stryker markets HydroSet (the predecessor synthetic bone substitute co-invented by RevBio CEO Brian Hess) and holds a licensing relationship with RevBio, giving it established bone adhesive/substitute distribution channels RevBio must eventually challenge.
Emerging players
- Bone Biologics: Bone Biologics is a clinical-stage company developing recombinant human bone morphogenetic protein (rhBMP) bone graft products for spinal fusion. It is a comparable early-stage orthobiologics peer competing in the same regenerative bone healing space with similar scale, stage, and capital profile.
- NovaBone Products: NovaBone Products manufactures bioactive glass and calcium phosphate-based synthetic bone graft substitutes used in dental, orthopaedic, and cranial procedures. It competes with TETRANITE in dental bone grafting and orthobiologic indications with established FDA-cleared products.
- Cerapedics: Cerapedics markets i-FACTOR, a synthetic small peptide bone graft substitute used in cervical spine fusion and orthopaedic procedures. It is a more direct functional comparator for RevBio's regenerative orthobiologic approach and competes for the same orthopaedic and dental bone grafting indications.
Direct peers
- Orthofix Medical: Orthofix Medical develops orthobiologics including bone growth stimulators, allografts, and synthetic bone graft substitutes used in fracture fixation and spinal fusion. It is a direct peer in the orthopaedic bone healing space where RevBio is pursuing extremity fracture and spine indications.
- Integra LifeSciences: Integra LifeSciences develops and markets DuraSeal dural sealant and other neurosurgical/cranial sealants and regenerative products. It is the most direct competitor to RevBio in the cranial flap fixation indication where RevBio just received FDA pivotal trial approval, with established neurosurgery sales channels and CMS reimbursement.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
RevBio social profiles
Digital presenceRevBio compliance and trust
Trust signalCompliance2 records
RevBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
RevBio leadership team
Management profileNumber of profiles
Profiles1 record
RevBio subsidiaries and ownership
Company hierarchySubsidiaries1 record
RevBio funding detail
Funding detailFunding overview
Funding rounds22 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RevBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RevBio
What does RevBio do?
RevBio develops and is commercializing TETRANITE, a patented, synthetic, injectable, self-setting, load-bearing, osteoconductive bone adhesive biomaterial. The product is engineered to bond bone-to-bone and bone-to-metal in wet surgical environments, replacing the need for metal fixation hardware in dental, cranial, orthopaedic, and veterinary procedures. RevBio is a clinical-stage medical device company running first-in-human clinical trials across multiple indications ahead of commercial launch.
Is RevBio a public or private company?
RevBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was RevBio founded?
RevBio was founded in 2014. It employs 11 to 50 people.
Where is RevBio based?
RevBio is headquartered in Lowell, United States, in the North America region.
How does RevBio make money?
Two revenue lines are on record. TETRANITE Bone Adhesive Sales are the primary driver. The others are technology Licensing.
Who are RevBio's main competitors?
Broad incumbents on record are Medtronic, Baxter International, Becton Dickinson (BD), Johnson & Johnson (DePuy Synthes) and Stryker Corporation. Emerging players are Bone Biologics, NovaBone Products and Cerapedics. Direct peers are Orthofix Medical and Integra LifeSciences.
Does RevBio have an API?
No public API is recorded for RevBio.
What industry is RevBio in?
RevBio's product category is Orthopedic Biomaterials. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.